Peter Lynch fit · Growth at a reasonable price (GARP)
Is Amicus Therapeutics, Inc. (FOLD) a Peter Lynch Stock?
Some GARP characteristics, but growth or valuation is stretched.
54/100
CMixed signals
2/6 criteria passed
+2 sector-quality lift. Top-quintile within its sector on 1 of 5 quality metrics. Raw pillar score 52 → lifted to 54 before grade derivation.
Peter Lynch's Criteria, Applied to FOLD
PEG ≤ 1.0
key-
EPS CAGR ≥ 15%
key-
Revenue CAGR ≥ 10%
20.0%
Net margin > 0
-4.3%
How FOLD Scores on Other Strategies
Live Financial Snapshot
Market cap
-
P/E (TTM)
-
ROIC (TTM)
-
Gross margin
-
Other Peter Lynch fit reports
Frequently Asked Questions
What is FOLD's Peter Lynch fit score?
FOLD scores 54/100 on our Peter Lynch fit engine - grade C. Some GARP characteristics, but growth or valuation is stretched.
Does Peter Lynch actually own FOLD?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends FOLD.
How often is this score updated?
FOLD's Peter Lynch fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Educational tool, not investment advice. Scores are computed from publicly-available financial data against published investing-strategy criteria. We do not claim that Peter Lynch personally owns or recommends FOLD.